This recombinant monoclonal antibody is designed as a research-grade biosimilar to the reference antibody described in US20220060312A1, targeting CCR8 (C-C chemokine receptor type 8). CCR8 is a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets, where it mediates chemotactic responses to CCL1 and CCL18. This receptor plays a critical role in immune regulation and has emerged as a significant target in immuno-oncology research, as tumor-infiltrating Tregs often exhibit high CCR8 expression, contributing to immunosuppressive tumor microenvironments. CCR8 is implicated in various cancers including colorectal, breast, and non-small cell lung cancer, as well as in inflammatory and allergic diseases.
The reference antibody represents a therapeutic candidate developed for selective depletion of CCR8-positive Tregs to enhance anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating CCR8 biology, Treg function, and immune checkpoint mechanisms. It supports studies examining tumor immunology, cancer immunotherapy development, and immune cell trafficking in disease contexts.
Email: support@cusabio.com
Distributors Worldwide